Abiraterone acetate, often recognized by the brand name Zytiga, is a robust medication primarily used in the management and treatment of prostate cancer. More specifically, it is typically combined with a corticosteroid and administered for conditions such as metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). This powerful oral, non-peptide, irreversible inhibitor of CYP17 blocks the manufacture of androgens in the testes, adrenal glands, and prostate cancer cells, thereby retarding the growth of hormone-sensitive prostate cancer cells.
Parent: Abiraterone
Parent: Abiraterone
Parent: Abiraterone
Parent: Abiraterone
![(3R,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate](https://veeprho.com/wp-content/uploads/2023/05/3R-8R-9S-10R-13S-14S-10-13-dimethyl-17-pyridin-3-yl-2-3-4-7-8-9-10-11-12-13-14-15-dodecahydro-1H-cyclopenta-a-phenanthren-3-yl20acetate.png "(3R,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate")
Parent: Abiraterone
Parent: Abiraterone
Parent: Abiraterone
Parent: Abiraterone
Parent: Abiraterone
Abiraterone is synthesized through various stages, and it could potentially contain several impurities and related compounds. These predominantly include isomers of abiraterone and minor trace amounts of solvents or reagents used in its synthesis. Regulatory authorities like the US FDA and European Medicines Agency strictly monitor and set permissible limits for such impurities to ensure the safety, efficacy, and quality of the drug.
Abiraterone is most commonly used to treat prostate cancer. It is particularly effective in treating metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).
No, abiraterone is not a form of chemotherapy. It is classified as an androgen biosynthesis inhibitor. It works by limiting the production of androgens, which prostate cancer cells need to grow.
Abiraterone works by inhibiting the action of an enzyme called ‘Cytochrome P17’. This enzyme is critical to the production of the androgens (sex hormones) that prostate cancer cells need to grow. By blocking this enzyme, abiraterone reduces the amount of these hormones in the body, thus slowing the growth of prostate cancer cells.
The life expectancy for patients treated with abiraterone can vary considerably based on multiple factors including the stage of the cancer, the individual’s overall health, and how well the individual responds to the treatment. However, studies suggest abiraterone may extend survival in men with advanced prostate cancer. Always consult with a healthcare provider for personalized information.
